DioGenX
diogenx.com
Actively hiring
Cardiometabolic Therapeutics
Health Care
Biotechnology
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$34.9M
3 rounds on record
Latest round
$30M
Series A · May 2023 · 3 yr ago
Team
11-50
employees, estimated range
Grants
$2.7M
1 grant · CORDIS
Backers
1
Omnes Capital
The money's age
Long since its last round
40 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Grant | Oct 2023 | $2.7M | — | CORDIS |
| Series A | May 2023 | $30M | — | bioworld.com |
| Seed | Jun 2020 | $4.9M | — | diogenx.com |
Backed byfrom the funds' portfolios and accelerator catalogs
Omnes Capital Similar startupsby what they do, their industry and backers
Akero Therapeutics is a clinical-stage company developing transformational therapies for people with metabolic dysfunction-associated…
Terrestrial is transforming the delivery of next-generation therapies, starting with GLP-1. Terrestrial.
Sparrow Pharmaceuticals is an emerging clinical-stage biopharmaceutical company developing novel, targeted therapies for disorders of…
Kailera is a late clinical-stage biotechnology company advancing a diversified pipeline of GLP-1 therapies to provide options for people…
WELCOME TO THE NEW HOME FOR MINISIS A very warm welcome to the new home for MINISIS products and solutions here at Soutron Global.
Welcome to Piano, the leading platform for data analytics, audience segmentation, and customer engagement. Discover how we help businesses…
News
DiogenX appoints Dr. Klara Owen as Chief Medical Officer
Marseille, France, November 12, 2024 - DiogenX, a biotech company focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr. Klara Owen as Chief Medical Officer."I am delighted to welcome Dr.
Read more
Report
DiogenX welcomes Eleanor L. Ramos as independent member of its Board of Directors
Marseille, France, September 9, 2024 - DiogenX, a biotech company focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Eleanor L. Ramos, MD, as an Independent Board Member."Dr. Ramos brings
Read more
Report
DiogenX strengthens Executive Committee with Hélène Sicard joining as Chief Development Officer
Marseille, France, July 25, 2024 - DiogenX, a biotech company focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Hélène Sicard, PhD, as Chief Development Officer.The appointment of Dr. Si
Read more
Report
Sunstone Life Science Ventures Fund IV invests in DiogenX, a biotech company developinga first-in-class regenerative treatment for type 1 diabetes
Sunstone Life Science Ventures Fund IV invests in DiogenX, a biotech company developing a first-in-class regenerative treatment for type 1.
Read more
Report
DiogenX lève 27,5 millions d'euros lors d'un tour de financement de série A pour faire avancer son traitement dans le diabète de type 1 MyPharma Editions
DiogenX, société de biotechnologie spécialisée dans la régénération des cellules bêta productrices d'insuline pour le traitement du diabète, a annoncé avoir finalisé un tour de financement de série A de 27,5 millions d'euros.
Read more
Report
Pro access
Upgrade to see all 11 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.